t
Fusion Antibodies plc announced on 19 September 2025 that its Annual Report and Accounts for the year ended 31 March 2025 and the Notice of its Annual General Meeting (AGM) are being posted to shareholders. The AGM will be held on Thursday, 16 October 2025, at 11:00 a.m. at the company's offices in Belfast.
| Date | 19 Sept 2025 |
| Time | 12:58:05 |
| Category | AGMs and other meetings |
| ID | 1048A |
Fusion Antibodies plc
("Fusion" or the "Company")
Posting of Annual Report & Notice of AGM
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Annual Report and Accounts for the year ended 31 March 2025 and the Notice of the Company's Annual General Meeting ("AGM") is being posted to shareholders today.
The Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here: https://www.fusionantibodies-ir.com/.
The AGM will be held on Thursday, 16 October 2025 at 11.00 a.m. at the offices of Fusion Antibodies plc, 1 Springbank Road, Springbank Industrial Estate, Belfast BT17 0QL.
Enquiries:
|
Investor questions on this announcement |
|
|
|
We encourage all investors to share questions on this announcement via our investor hub |
||
|
|
|
|
|
Fusion Antibodies plc |
www.fusionantibodies.com |
|
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
Allenby Capital Limited |
Tel: +44 (0) 20 3328 5656 |
|
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
|
|
|
|
|
|
|
|
|
|
|
Shard Capital Partners LLP |
|
|
|
Damon Heath (Joint Broker) |
Tel: +44 (0) 207 186 9952 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
|
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.